Restless Legs Syndrome - Pipeline Review, H1 2014

Restless Legs Syndrome - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Restless Legs Syndrome - Pipeline Review, H1 2014’, provides an overview of the Restless Legs Syndrome’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Restless Legs Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Restless Legs Syndrome and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Restless Legs Syndrome
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Restless Legs Syndrome and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Restless Legs Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Restless Legs Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Restless Legs Syndrome
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Restless Legs Syndrome pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Restless Legs Syndrome Overview 6
Therapeutics Development 7
Pipeline Products for Restless Legs Syndrome - Overview 7
Pipeline Products for Restless Legs Syndrome - Comparative Analysis 8
Restless Legs Syndrome - Therapeutics under Development by Companies 9
Restless Legs Syndrome - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Unknown Stage Products 14
Restless Legs Syndrome - Products under Development by Companies 15
Restless Legs Syndrome - Companies Involved in Therapeutics Development 16
Purdue Pharma L.P. 16
Ligand Pharmaceuticals, Inc. 17
Hisamitsu Pharmaceutical Co., Inc. 18
Omeros Corporation 19
Ascendis Pharma A/S 20
Serina Therapeutics, Inc. 21
Restless Legs Syndrome - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Combination Products 23
Assessment by Target 24
Assessment by Mechanism of Action 27
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 33
(oxycodone hydrochloride + naloxone hydrochloride) - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
aplindore fumarate - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
ropinirole hydrochloride - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
OMS-527 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
SER-214 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
pramipexole - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Restless Legs Syndrome - Recent Pipeline Updates 41
Restless Legs Syndrome - Dormant Projects 43
Restless Legs Syndrome - Discontinued Products 44
Restless Legs Syndrome - Product Development Milestones 45
Featured News & Press Releases 45
Dec 05, 2013: Safinamide Marketing Authorization Application Submitted To The European Medicines Agency 45
Feb 22, 2013: Otsuka Pharma Announces Launch Of Neupro Patch In Japan 45
Dec 25, 2012: UCB's Neupro Obtains Japanese Approval For Treatment Of Parkinson’s Disease And Restless Legs Syndrome 46
Jul 16, 2012: UCB Launches Neupro In US To Treat Parkinson’s Disease And Restless Legs Syndrome 46
Jun 21, 2012: Observational Study Shows UCB's Neupro Improves Day- And Night-Time Symptoms Of Restless Legs Syndrome 48
Apr 25, 2012: UCB To Present Data On Post-Hoc Analysis Of Neupro Phase III Trial To Treat Restless Legs Syndrome At AAN Annual Meeting 49
Apr 20, 2012: UCB To Present New Data On Neupro At 64th AAN Annual Meeting 51
Apr 03, 2012: UCB's Neupro Receives Approval From FDA For Parkinson’s Disease And Restless Legs Syndrome 52
Jan 13, 2012: Otsuka Pharmaceutical Files New Drug Application For Rotigotine Patch In Japan 53
Dec 16, 2011: Pfizer Reports Positive Results From Phase III Trial Of Lyrica Capsules CV In Restless Legs Syndrome 53
Appendix 55
Methodology 55
Coverage 55
Secondary Research 55
Primary Research 55
Expert Panel Validation 55
Contact Us 56
Disclaimer 56

List of Tables
Number of Products under Development for Restless Legs Syndrome, H1 2014 7
Number of Products under Development for Restless Legs Syndrome - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 10
Comparative Analysis by Late Stage Development, H1 2014 11
Comparative Analysis by Clinical Stage Development, H1 2014 12
Comparative Analysis by Early Stage Development, H1 2014 13
Comparative Analysis by Unknown Stage Development, H1 2014 14
Products under Development by Companies, H1 2014 15
Restless Legs Syndrome - Pipeline by Purdue Pharma L.P., H1 2014 16
Restless Legs Syndrome - Pipeline by Ligand Pharmaceuticals, Inc., H1 2014 17
Restless Legs Syndrome - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H1 2014 18
Restless Legs Syndrome - Pipeline by Omeros Corporation, H1 2014 19
Restless Legs Syndrome - Pipeline by Ascendis Pharma A/S, H1 2014 20
Restless Legs Syndrome - Pipeline by Serina Therapeutics, Inc., H1 2014 21
Assessment by Monotherapy Products, H1 2014 22
Assessment by Combination Products, H1 2014 23
Number of Products by Stage and Target, H1 2014 26
Number of Products by Stage and Mechanism of Action, H1 2014 29
Number of Products by Stage and Route of Administration, H1 2014 31
Number of Products by Stage and Molecule Type, H1 2014 32
Restless Legs Syndrome Therapeutics - Recent Pipeline Updates, H1 2014 41
Restless Legs Syndrome - Dormant Projects, H1 2014 43
Restless Legs Syndrome - Discontinued Products, H1 2014 44

List of Figures
Number of Products under Development for Restless Legs Syndrome, H1 2014 7
Number of Products under Development for Restless Legs Syndrome - Comparative Analysis, H1 2014 8
Number of Products under Development by Companies, H1 2014 9
Assessment by Monotherapy Products, H1 2014 22
Number of Products by Top 10 Target, H1 2014 24
Number of Products by Stage and Top 10 Target, H1 2014 25
Number of Products by Top 10 Mechanism of Action, H1 2014 27
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 28
Number of Products by Top 10 Route of Administration, H1 2014 30
Number of Products by Stage and Top 10 Route of Administration, H1 2014 31
Number of Products by Stage and Top 10 Molecule Type, H1 2014 32